209 related articles for article (PubMed ID: 27488320)
1. Neurokinin-1 receptor antagonists as antitumor drugs in gastrointestinal cancer: A new approach.
Muñoz M; Coveñas R
Saudi J Gastroenterol; 2016; 22(4):260-8. PubMed ID: 27488320
[TBL] [Abstract][Full Text] [Related]
2. The NK-1 receptor antagonist L-732,138 induces apoptosis in human gastrointestinal cancer cell lines.
Muñoz M; Rosso M; Coveñas R
Pharmacol Rep; 2017 Aug; 69(4):696-701. PubMed ID: 28550801
[TBL] [Abstract][Full Text] [Related]
3. Cancer progression and substance P.
Coveñas R; Muñoz M
Histol Histopathol; 2014 Jul; 29(7):881-90. PubMed ID: 24535838
[TBL] [Abstract][Full Text] [Related]
4. Involvement of substance P and the NK-1 receptor in pancreatic cancer.
Muñoz M; Coveñas R
World J Gastroenterol; 2014 Mar; 20(9):2321-34. PubMed ID: 24605029
[TBL] [Abstract][Full Text] [Related]
5. The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs.
Munoz M; Covenas R; Esteban F; Redondo M
J Biosci; 2015 Jun; 40(2):441-63. PubMed ID: 25963269
[TBL] [Abstract][Full Text] [Related]
6. Neurokinin-1 receptor: a new promising target in the treatment of cancer.
Muñoz M; Coveñas R
Discov Med; 2010 Oct; 10(53):305-13. PubMed ID: 21034671
[TBL] [Abstract][Full Text] [Related]
7. Glioma and Neurokinin-1 Receptor Antagonists: A New Therapeutic Approach.
Muñoz M; Coveñas R
Anticancer Agents Med Chem; 2019; 19(1):92-100. PubMed ID: 29692265
[TBL] [Abstract][Full Text] [Related]
8. NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011.
Muñoz M; Martinez-Armesto J; Coveñas R
Expert Opin Ther Pat; 2012 Jul; 22(7):735-46. PubMed ID: 22697287
[TBL] [Abstract][Full Text] [Related]
9. Triple Negative Breast Cancer: How Neurokinin-1 Receptor Antagonists Could Be Used as a New Therapeutic Approach.
Muñoz M; Rosso M; Coveñas R
Mini Rev Med Chem; 2020; 20(5):408-417. PubMed ID: 31721701
[TBL] [Abstract][Full Text] [Related]
10. The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.
Coveñas R; Rodríguez FD; Robinson P; Muñoz M
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958914
[TBL] [Abstract][Full Text] [Related]
11. The NK-1 receptor: a new target in cancer therapy.
Muñoz M; Rosso M; Coveñas R
Curr Drug Targets; 2011 Jun; 12(6):909-21. PubMed ID: 21226668
[TBL] [Abstract][Full Text] [Related]
12. The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists.
Muñoz M; González-Ortega A; Rosso M; Robles-Frias MJ; Carranza A; Salinas-Martín MV; Coveñas R
Peptides; 2012 Dec; 38(2):318-25. PubMed ID: 23026680
[TBL] [Abstract][Full Text] [Related]
13. NK-1 receptor antagonists: a new generation of anticancer drugs.
Munoz M; Covenas R
Mini Rev Med Chem; 2012 Jun; 12(7):593-9. PubMed ID: 22512565
[TBL] [Abstract][Full Text] [Related]
14. The antiproliferative action of [D-Arg(1), D-Phe(5), D-Trp(7,9), LEU(11)] substance P analogue antagonist against small-cell- and non-small-cell lung cancer cells could be due to the pharmacological profile of its tachykinin receptor antagonist.
Munoz M; Recio S; Rosso M; Redondo M; Covenas R
J Physiol Pharmacol; 2015 Jun; 66(3):421-6. PubMed ID: 26084224
[TBL] [Abstract][Full Text] [Related]
15. Neurokinin-1 Receptor Antagonists against Hepatoblastoma.
Muñoz M; Rosso M; Coveñas R
Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31466222
[TBL] [Abstract][Full Text] [Related]
16. The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer.
Muñoz M; González-Ortega A; Salinas-Martín MV; Carranza A; Garcia-Recio S; Almendro V; Coveñas R
Int J Oncol; 2014 Oct; 45(4):1658-72. PubMed ID: 25175857
[TBL] [Abstract][Full Text] [Related]
17. Involvement of substance P and the NK-1 receptor in cancer progression.
Muñoz M; Coveñas R
Peptides; 2013 Oct; 48():1-9. PubMed ID: 23933301
[TBL] [Abstract][Full Text] [Related]
18. A new frontier in the treatment of cancer: NK-1 receptor antagonists.
Muñoz M; Rosso M; Coveñas R
Curr Med Chem; 2010; 17(6):504-16. PubMed ID: 20015033
[TBL] [Abstract][Full Text] [Related]
19. The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines.
Muñoz M; González-Ortega A; Coveñas R
Invest New Drugs; 2012 Apr; 30(2):529-40. PubMed ID: 21120581
[TBL] [Abstract][Full Text] [Related]
20. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]